CN109320510B - Preparation method of Maropitan free base - Google Patents
Preparation method of Maropitan free base Download PDFInfo
- Publication number
- CN109320510B CN109320510B CN201811427521.XA CN201811427521A CN109320510B CN 109320510 B CN109320510 B CN 109320510B CN 201811427521 A CN201811427521 A CN 201811427521A CN 109320510 B CN109320510 B CN 109320510B
- Authority
- CN
- China
- Prior art keywords
- reaction
- formula
- preparation
- free base
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to a preparation method of free maririptan alkali, and the reaction relates to (2S,3R) -2-benzhydrylquinuclidine-3-alcohol and R1SO2Cl or (CF)3SO2)2And reacting the compound IV with 2-methoxy-5-tert-butyl-benzylamine in the presence of alkali and a solvent to obtain free maripidan alkali.
Description
Technical Field
The invention belongs to the technical field of methods for synthesizing bulk drugs, and particularly relates to preparation of bulk drug maririptan free base.
Background
Maropintan Citrate (Maropintant Citrate), a receptor anticaking agent for neurokinin type 1 (NK1), acts on the central nervous system by inhibiting substance P, a key neurotransmitter responsible for emesis. The maririptan citrate belongs to one of alternative quinuclidine medicaments, and due to obvious curative effect, the medicament is approved by the FDA in 2007 to prevent and treat acute emesis of dogs and is subsequently approved to be used as a prescription external medicament for cats. The citric acid maropiptan has two dosage forms, and the citric acid maropiptan for injection is applied to preventing and treating acute vomiting of dogs; the tablet of the citric acid, the maririptan citrate, is used for preventing acute vomiting of dogs and vomiting caused by motion sickness; both can be used as external medicine for cat. The import registration of the maropiptan citrate is approved by the department of agriculture in China in 2016 and 5 months, and the maropiptan citrate is also used for preventing and treating acute emesis of dogs.
Maropritan citrate is also known as CJ-11,972, under the trade name Cerenia (antiemetic), and was developed by the original research of Peucedanum. The molecular weight of the citric acid, maririptan, is 678.82, and the chemical name is (2S,3S) -2-benzhydryl-N- (5-tert-butyl-2-methoxybenzyl) -3-amino-quinuclidine citrate monohydrate. The chemical structural formula is as follows:
documents WO2004035575, WO2005075473 and the like disclose and report a synthetic method of mariupitan; the synthetic route of the method requires 8-step reaction to realize the preparation of free marimastat base, wherein a phenyl magnesium bromide format reagent which is difficult to control and cuprous dimethyl sulfide bromide (CuBr (CH)) are involved3)2S) participating in Michael addition reactions, multi-step pressure hydrogenation reactions, and the like.
The specific reaction formula is as follows:
the method for synthesizing the free alkali of the maririptan has the advantages of long route and low yield (the total yield of 8-step reaction is only about 10%), and various precious metals such as Ti, Pt, Pd and the like are used in the reaction process, so that the cost is high, and a large amount of solvent and adsorbent are consumed for removing the precious metal residues. Therefore, the development of a new method for synthesizing the marapittanan is particularly important for the industrialized production of the drug.
Disclosure of Invention
The invention aims to provide a novel method for preparing free macriptan base, aiming at avoiding the defects of large use of noble metal reagents and chiral resolution reagents and low total yield in the original patents.
The synthetic route of the invention is as follows:
the first step of the reaction involves the reaction of (S) -2-benzhydrylquinuclidin-3-one (formula I) under Na/I-PrOH/Toluene conditions [0009] to produce (2S,3R) -2-benzhydrylquinuclidin-3-ol (formula II).
The second step of the reaction is carried out by reacting a compound of formula II with R in the presence of a base and a solvent1SO2Cl or (CF)3SO2)2And reacting O to obtain the hydroxyl protected compound shown as the formula IV.
The solvent used in the second reaction stage is CH2Cl2,THF,2-MeTHF,Dioxane,CH3CN。
The base used in the second reaction stage is Pyridine, Et3N,DIPEA,Morpholine,DMAP。
R of the formula III1Is methyl, p-methylphenyl or phenyl.
R of the formula IV2Is methylsulfonyl (Ms), p-toluenesulfonyl (Ts), trifluoromethanesulfonyl (Tf), phenylsulfonyl (PhSO)2-)。
The third step of the reaction is that the compound shown in the formula IV reacts with 2-methoxy-5-tert-butyl-benzylamine in the presence of alkali and solvent to obtain free alkali of the maririptan.
The base used in the third step of the reaction is Et3N,DIPEA,Pyridine,Morpholine,DMAP。
The solvent used in the third step of the reaction is THF,2-MeTHF, DMF, CH2Cl2，Dioxane，CH3CN，TMBE。
The method has the advantages of short synthetic route, high total yield, easy commercial mass purchase of used reagents, simple process operation, no need of using noble metals such as Pd, Ti, Pt and the like, and suitability for industrial amplification production of free alkali of the maririptan.
Detailed Description
The following exemplary embodiments are provided to illustrate the present invention, and simple replacement and modification of the present invention by those skilled in the art are within the technical scheme of the present invention.
EXAMPLE one preparation of (2S,3R) -2-benzhydrylquinuclidin-3-ol (formula II)
Adding (S) -2-benzhydrylquinuclidin-3-one (formula I) (130g,446mmol,1.0eq.) and toluene (1.8L) into a 5L reaction bottle, heating the system after the addition, refluxing and dehydrating, and removing a small amount of water in the reaction system. Then, small pieces of Na metal (50g,2175mmol) were slowly added to the system under reflux, and after the addition was completed, i-PrOH (450mL) was slowly added under reflux. The system is refluxed and reacts for 1.5 hours, then is naturally cooled to room temperature, and methanol (1L) is added into the reaction system to quench the reaction. Concentrating under reduced pressure to remove solvent, adding H into residue2O (2L) and CH2Cl2(1L), the system is stirred for 3 hours and then is kept stand, an organic phase is separated out, and a water phase CH is formed2Cl2(3X 500mL) was extracted three times, the organic phases combined, the solvent removed by concentration under high vacuum and the residue purified by column chromatography to give (2S,3R) -2-benzhydrylquinuclidin-3-ol (formula II) (pale yellow solid, 94.3g, 72.1%).
EXAMPLE two (2S,3R) -2-benzhydryl-3-methanesulfonyloxy-quinine (formula IV, R)2Ms) preparation
To a reaction flask was added (2S,3R) -2-benzhydrylquinuclidin-3-ol (formula II) (5.0g,17mmol) and CH2Cl2(15 mL). The reaction was cooled to 5 ℃ in an ice salt bath, and then Pyridine (25mL) and MsCl (4.0g,34.9mmol) were slowly added through a dropping funnel. After the addition, the system is naturally heated to room temperature and stirred for 5 hours, then the system is heated to reflux reaction for 2 hours, and then the system is naturally cooled to room temperature. The system was charged with HCl solution (2N in H)2O) adjusting the pH value of the system to 8-9, and then adding CHCl3Extracting with 3 × 120mL for three times, mixing organic phases, concentrating the organic phase under high vacuum and reduced pressure to remove solvent, and purifying the residue by column chromatography to obtain (2S,3R) -2-benzhydryl-3-methylsulfonyloxy-quinine (formula IV, R)2＝Ms)(5.15g,81.5％)。
EXAMPLE III preparation of free base of Marupitan
Adding (2S,3R) -2-benzhydryl-3-methylsulfonyloxy-quinine (formula IV, R) into a reaction bottle2Ms) (4.5g,12.11mol) and DMF (b)20 mL). After the addition was completed, triethylamine (4.9g,48.42mmol,4.0eq.) and 2-methoxy-5-tert-butyl-benzylamine (3.50g,18.11mol) were added to the system. After the addition, the system is heated to 100 ℃ for reaction until the starting material disappears after TLC tracking. Naturally cooling the system to room temperature, removing the organic solvent in the system under high vacuum and reduced pressure, and adding CH into the residue2Cl2(60mL) and H2O (60mL), the organic phase was separated and the aqueous phase was treated with CH2Cl2Extraction (3X 30 mL). The organic phases were combined, washed with saturated brine (50mL), anhydrous Na2SO4After drying, desolventizing under reduced pressure and column chromatography of the residue yielded free marimastat base (4.94g, 87.1%).
Example four (2S,3R) -2-benzhydryl-3-trifluoromethanesulfonyloxy-quinine (formula IV, R)2Tff) preparation
To the reaction flask was added (2S,3R) -2-benzhydrylquinuclidin-3-ol (formula II) (12.2g,41.6mmol) and anhydrous THF (40 mL). The reaction system is cooled to about 5 ℃ by an ice salt bath, and then DIPEA (50mL) and Tf are slowly added through a dropping funnel2O (23.5g,83.3 mmol). After the addition, the system is naturally warmed to room temperature and stirred for 24 hours. The system was charged with HCl solution (2N in H)2O) adjusting the pH value of the system to 8-9, and then adding CHCl3Extracting for three times (3 × 200mL), combining organic phases, concentrating the organic phases under high vacuum and reduced pressure to remove the solvent, and purifying the residue by column chromatography to obtain (2S,3R) -2-benzhydryl-3-trifluoromethanesulfonyloxy-quinine (formula IV, R)2＝Tf)(13.48g,76.2％)。
EXAMPLE V preparation of free Marupitan base
Adding (2S,3R) -2-benzhydryl-3-trifluoromethanesulfonyloxy-quinine (formula IV, R) into a reaction bottle2Tf) (12.0g,28.2mol) and 2-MeTHF (50 mL). After the addition was completed, DMAP (10.34g,84.64mmol) and 2-methoxy-5-tert-butyl-benzylamine (6.55g,33.89mol) were added to the system. After the addition was complete, the system was warmed to reflux until the TLC tracked disappearance of starting material. Naturally cooling the system to room temperature, removing the organic solvent in the system under high vacuum and reduced pressure, and adding CH into the residue2Cl2(120mL) and H2O (120mL), the organic phase is separated off and the aqueous phase CH2Cl2Extraction (3X 60 mL). Combining the organic phases with organicWashed with brine (120mL) and anhydrous Na2SO4After drying, desolventizing under reduced pressure and column chromatography of the residue, the free base of maririptan (10.92g, 82.6%) was obtained.
Claims (2)
1. A process for the preparation of free base of macropitan having the formula:
2. the process for preparing a free base of maleopiptan according to claim 1, wherein the base used in the reaction is triethylamine, N, N-diisopropylethylamine, pyridine, morpholine, 4-dimethylaminopyridine; the solvent used in the reaction is tetrahydrofuran, 2-methyltetrahydrofuran, N, N-dimethylformamide, dichloromethane, dioxane, acetonitrile or methyl tert-butyl ether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811427521.XA CN109320510B (en) | 2018-11-27 | 2018-11-27 | Preparation method of Maropitan free base |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811427521.XA CN109320510B (en) | 2018-11-27 | 2018-11-27 | Preparation method of Maropitan free base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109320510A CN109320510A (en) | 2019-02-12 |
| CN109320510B true CN109320510B (en) | 2021-04-27 |
Family
ID=65259282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811427521.XA Active CN109320510B (en) | 2018-11-27 | 2018-11-27 | Preparation method of Maropitan free base |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109320510B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110713488A (en) * | 2019-11-28 | 2020-01-21 | 海门慧聚药业有限公司 | Crystal form of Maropiptan free base and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560510A (en) * | 1969-03-05 | 1971-02-02 | Aldrich Chem Co Inc | 2-benzhydrylquinuclidines |
| WO2002085901A1 (en) * | 2001-04-19 | 2002-10-31 | Pharmacia & Upjohn Company | Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) |
| CN1914202A (en) * | 2004-02-02 | 2007-02-14 | 辉瑞产品有限公司 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine |
| CN106977512A (en) * | 2017-05-04 | 2017-07-25 | 海门慧聚药业有限公司 | The method for preparing the smooth free alkali of horse sieve |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781390A1 (en) * | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
-
2018
- 2018-11-27 CN CN201811427521.XA patent/CN109320510B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560510A (en) * | 1969-03-05 | 1971-02-02 | Aldrich Chem Co Inc | 2-benzhydrylquinuclidines |
| WO2002085901A1 (en) * | 2001-04-19 | 2002-10-31 | Pharmacia & Upjohn Company | Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) |
| CN1914202A (en) * | 2004-02-02 | 2007-02-14 | 辉瑞产品有限公司 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine |
| CN106977512A (en) * | 2017-05-04 | 2017-07-25 | 海门慧聚药业有限公司 | The method for preparing the smooth free alkali of horse sieve |
Non-Patent Citations (2)
| Title |
|---|
| 《A Concise Enantioselective Synthesis of (+)-L-733,060 and (+)-T-2328 via Sequential Proline Catalysis》;Komal G. Lalwani et al.;《Syn lett》;20160204;第27卷;第1339-1343页 * |
| 《Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist》;Zunhua Yang et al.;《Bioorganic & Medicinal Chemistry Letters》;20170402;第27卷;第2515-2519页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109320510A (en) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108047261B (en) | Preparation method of clitorium | |
| ES2924738T3 (en) | Process for the preparation of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo Methyl [7]annulene-2-carboxylate and a salt thereof | |
| JP6764039B2 (en) | Tricyclic compounds and their applications | |
| CN110627736B (en) | Method for recycling 1-phenyl-5-hydroxy tetrazole | |
| CN103664912B (en) | A kind of synthesis technique of prucalopride | |
| CN114437031B (en) | Synthesis method of 6-methyl nicotine | |
| CN109320510B (en) | Preparation method of Maropitan free base | |
| CN105330582A (en) | Preparation method for (R)-4-hydroxy-2-oxo-1-pyrrolidine acetamide | |
| CN106749259A (en) | A kind of synthetic method of cyclopenta pyrimido azoles | |
| CN105175329A (en) | New synthesis route and method of bedaquiline racemate | |
| CN101735134A (en) | Chiral 3-hydroxy pyrrolidone compound and preparation method and application thereof | |
| CN108299216A (en) | The preparation method of 2,6- of one kind dimethyl-l-tyrosine | |
| CN106083539B (en) | A kind of synthetic method of list fluorine methoxyl group or the deuterated methoxy base class compound of single fluorine | |
| CN107365301B (en) | Synthesis method of crizotinib and preparation method of intermediate thereof | |
| CN105745191A (en) | Method for preparing silodosin and intermediate thereof | |
| CN103922986A (en) | Vildagliptin, vildagliptin analogues and vildagliptin intermediate, and preparation methods of three and application | |
| CN103113408A (en) | Novel method for preparing fosfomycin phenylethylamine | |
| CN109265385B (en) | Synthesis process of chiral catalyst | |
| CN109020977B (en) | Preparation method of Acaraburtinib | |
| CN107629039B (en) | The preparation method and intermediate of deuterated acrylamide | |
| CN101088999A (en) | Process of synthesizing 3-amino quinine dihydrochloride | |
| CN111362935A (en) | Synthesis method of N-hydroxy tropisetron | |
| CN107216302A (en) | A kind of fluorine can draw fixed synthetic method | |
| CN113956268B (en) | 6-bromo-1-chlorobenzothiophene [2,3-c ] pyridine and synthetic method | |
| CN113754630B (en) | Synthetic method of alpha-lipoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu Applicant after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu Applicant before: WISDOM PHARMACEUTICAL Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu Patentee after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu Patentee before: Jiangsu Huiju Pharmaceutical Co.,Ltd. |